Delivery Order SPE2DB22D1017-SPE2DB25FG9DH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,026.45 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on August 14, 2025, with a completion date of August 15, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract and is part of a larger Indefinite Delivery Contract (IDC) vehicle—the DLA Troop Support Medical contract SPE2DX valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp,...
- The Defense Logistics Agency awarded a $7,869.72 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Otezla 30 mg, a pharmaceutical product for treating autoimmune conditions. This competitive award, issued on July 22, 2025, represents a firm fixed-price contract with a completion date of July 23, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $18,874.86 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 20, 2025, with a completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,576.65 to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count supply) on July 24, 2025, with a completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Otezla is a prescription immunosuppressant medication used to treat various inflammatory...
- The Defense Logistics Agency awarded a $1,311.62 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract action under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $23,783.06 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed-price contract valued at $2,623.24. The award was issued on August 1, 2025, with an ultimate completion date of August 4, 2025, and represents a non-set-aside, competitively awarded transaction. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $17,101.64 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packages) on August 22, 2025, with an ultimate completion date of August 25, 2025. The contract utilizes firm fixed price pricing with no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work...
- The Defense Logistics Agency awarded a delivery order valued at $6,561.63 to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (quantity: 60) on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $6,654.43. This non-set-aside, competitively awarded delivery order was executed on August 12, 2025, with an ultimate completion date of August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9DHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Otezla 30 mg tablets (60-count packages) with a ceiling value of $4,610.09. This firm fixed-price delivery order was awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a competitive award with no set-aside designation. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Otezla, an immunosuppressant used to treat inflammatory conditions including psoriasis and psoriatic arthritis, represents the type of specialized pharmaceutical commodity within the company's extensive federal medical procurement portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 8/7/25 |